Physician profile
Philip Robert Pinter
NPI 1598397820
$3,022.34
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,107 · 2022: $1,461 · 2023: $348 · 2024: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $454.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $563.46 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $375.86 | 2021-2023 | Ajovy |
| Avanir Pharmaceuticals, INC. | $298.50 | 2021-2022 | |
| Amgen INC. | $189.52 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $186.97 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $171.88 | 2022-2023 | |
| Lilly USA, LLC | $146.37 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $129.36 | 2021-2023 | Ztlido |
| Pfizer INC. | $119.16 | 2023 | |
| Vertos Medical, INC. | $110.54 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $97.85 | 2021 | |
| Arbor Pharmaceuticals, INC. | $97.13 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $95.00 | 2022 | |
| Redhill Biopharma INC. | $62.51 | 2021 | |
| Painteq LLC | $50.73 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $42.05 | 2021-2024 | Rexulti |
| Axsome Therapeutics, INC. | $39.22 | 2022 | |
| Impel Pharmaceuticals INC. | $39.02 | 2022-2023 | Trudhesa |
| Almatica Pharma LLC | $23.77 | 2021 | |
| Ironshore Pharmaceuticals INC. | $21.88 | 2024 | |
| Boston Scientific Corporation | $20.93 | 2022 | |
| Hikma Pharmaceuticals USA | $18.92 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $17.94 | 2021 | |
| Corium, LLC | $17.19 | 2024 | Azstarys |
| Horizon Therapeutics Plc | $16.25 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.05 | 2024 | Caplyta |
| Biodelivery Sciences International, INC. | $15.52 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.00 | 2024 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $13.69 | 2024 | Trintellix |
| Ibsa Pharma INC. | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Pinter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.